American Heart Journal
Volume 156, Issue 3 , Pages 527.e1-527.e9 , September 2008

Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study

  • Jean-Marc Davy, MD, PhD

      Affiliations

    • Cardiology Department, University Hospital, CHU Montpellier, Montpellier, France
    • Corresponding Author InformationReprint requests: Jean-Marc Davy, MD, PhD, Département de Cardiologie, Centre Hospitalier Universitaire de Montpellier, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.
    • ,
  • Martin Herold, MD

      Affiliations

    • University Hospital Kral Vinohrady, Prague, Czech Republic
    • ,
  • Christer Hoglund, MD

      Affiliations

    • Stockholm Heart Centre, Stockholm, Sweden
    • ,
  • Alphons Timmermans, MD

      Affiliations

    • Medisch Spectrum Twente, Enschede, Netherlands
    • ,
  • Antonio Alings, MD, PhD

      Affiliations

    • Amphia Hospital, Molengracht, Breda, Netherlands; and the Working Group on Cardiovascular Research, Netherlands (WCN)
    • ,
  • David Radzik, MD

      Affiliations

    • Sanofi-Aventis, Paris, France
    • ,
  • Louis Van Kempen, MD, PhD

      Affiliations

    • Hospital, Velp, Netherlands
    • ,
  • for the ERATO Study Investigators

      Affiliations

    • for a full list of the ERATO Study Investigators, see Appendix A.

Received 13 June 2007 ,Accepted 9 June 2008.

References 

  1. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–241
  2. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049–1056
  3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation. 2006;114:e257–e354
  4. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  5. Testa L, Biondi-Zoccai G, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J. 2005;26:2000–2006
  6. Denus S, Sanoski SA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation. A meta-analysis. Arch Intern Med. 2005;165:258–262
  7. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc). 2006;42(2):75–86
  8. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481–1487
  9. Singh BN, Connolly SJ, Crijns HGJM, et al. for the EURIDIS and ADONIS Investigators Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–999
  10. Hooymans PM, Merkus FW. Current status of cardiac glycoside drug interactions. Clin Pharm. 1985;4:404–413
  11. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–920
  12. Olshansky B, Sami M, Rubin A, et al. Use of amiodarone for atrial fibrillation in patients with pre-existing pulmonary disease in the AFFIRM study. Am J Cardiol. 2005;95:404–405
  13. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64:785–791
  14. Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: a Placebo-controlled, double-blind, parallel arm trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. J Cardiovasc Electrophysiol. 2008;19:69–73

 The ERATO study was sponsored by Sanofi-Aventis, Paris, France.

PII: S0002-8703(08)00477-8

doi: 10.1016/j.ahj.2008.06.010

American Heart Journal
Volume 156, Issue 3 , Pages 527.e1-527.e9 , September 2008

Article Tools

* Image Usage & Resolution